Sunday 30 November 2014

Next Generation Sequencing Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast

MarketResearchReports.Biz presents this most up-to-date research on "Research Report On Global Next Generation Sequencing Technologies Market" Industry Emerging Opportunities, Trends, Size, Drivers, Strategies, Products And Competitive Landscape Research Report 2020

"Next generation Sequencing (NGS) has revolutionized the way the human genomes are being sequenced now a days. The time and cost to sequence has tremendously reduced since the first human genome was sequenced, which took a decade time and around $3 billion. According to experts, in the coming years, a human genome can be sequenced at a cost of $1,000 in one to two days. In the last five years the sequencing cost has rapidly reduced and this is supposed to have a huge impact on the NGS market in the coming years. Until recently, uses of Next Generation Sequencing tools were limited to research Nowadays, NGS technologies have found applications mainly in two fields clinical diagnostics and infectious diseases. This report describes both current and future applications of NGS.

The global Next Generation Sequencing market is poised to grow at a CAGR of more than 20% to reach around $5.0 billion by 2020. The NGS market assessment was made based on products, technologies, end users, applications and geography. The NGS products market is further divided into instruments and reagents, services and workflow products. The instruments and consumables is the largest segment with a share of around half of the market in 2013. The fastest growing segment is the services with a highest CAGR during the forecast period. The major players are interested in services segment as it provides additional revenue for the company at the same time, increases the sales of instruments and reagents.

NGS technology is segmented into targeted resequencing, whole exome sequencing, RNA sequencing, whole genome sequencing, ChIP sequencing, de novo sequencing and methyl sequencing. Among these targeted re-sequencing technology accounted for the largest share of more than 25% of the technology market in 2013 and is expected to grow at a strong CAGR during the forecast period. Whole genome sequencing is poised to grow at the highest CAGR and expected to reach a share of more than 15% of the total market by 2020. Targeted resequencing and whole genome sequencing technologies are the prospective technologies as various targeted disease based NGS assays and panels are emerging and use of personalized medicine transforms with the understanding of individual’s whole genome imprint.
The NGS market by end users is divided into academics, hospitals and clinics, biotech and pharma and other end users, which include nonprofit organizations and commercial labs Out of these end users, academic research holds the largest share of the end user market in 2013. The fastest growing segment is hospitals and clinics which has the highest CAGR during the forecast period. Currently academic institutes dominate the market but hospitals along with clinical laboratories are supposed to be the leading segment in the coming years as clinical NGS applications is rapidly rising.The NGS applications market is classified into clinical and non-clinical applications. By application type, the market is segmented into oncology, genetic screening, infectious diseases, drug & biomarker discovery, molecular epidemiology, agriculture and other applications. Among the overall applications market oncology holds the lions share in 2013, Infectious diseases is expected to grow at the highest CAGR during the forecast period.

To Buy The Copy of This Report Visit:http://www.marketresearchreports.biz/sample/sample/234401

The major factors driving the NGS market include the reduced cost and high speed of NGS technology, increased use in the clinical segment, new application areas of NGS and switch over from microarrays to NGS. However, the standardization of NGS for clinical use, complexity in data interpretation, shortage of skilled labor and dependence of grants and funding for NGS infrastructure are restraining the market growth. The factors such as demand for NGS technology especially in drug discovery and development, growth of personalized medicine using NGS, increased medical spending along with the rise in incidences of chronic diseases are providing opportunities for the market growth.  

Further, the NGS market is segmented by geography into North America, Europe, Asia-pacific and Rest of the World. North America holds the largest share of the global NGS market accounting for around more than 40% in 2013 and Asia-Pacific is the fastest growing region with a CAGR of more than 20% during the forecast period.

The major players operating in the NGS market are Illumina Inc (U.S.), Thermo Fisher Scientific (U.S.), Hoffmann-La Roche Ltd (Switzerland), Pacific Bioscieces (U.S.) Agilent Technologies (U.S.), BGI (Beijing Genomics Institute) (China), Qiagen (Netherlands), Biomatters Ltd (New Zealand), and Genomatix Software GmbH (Germany).

This report provides in-depth market assessment across the major geographies such as:
North America
Europe
Asia-Pacific (APAC)
Rest of the World (RoW)

Reasons to Buy:
Next Generation Sequencing market revenue and market volume 
Next Generation Sequencing market assessment of sequencing runs by end users across the globe 
Key insights on emerging applications in the clinical segment
Major player profiles

No comments:

Post a Comment